Dramatic improvement of generalized prurigo nodularis with dupilumab

Călugăreanu, Andreea; Lepelletier, C.; Masson, Adèle de; Rybojad, M.; Bagot, M.; Bouaziz, J.‐D.

doi:10.1111/jdv.15584

Cited by 31 publications

(21 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calugareanu et al () reported a case of a patient with a history of atopy, who was treated for 8 months with dupilumab (600 mg initial dose, followed by 300 mg every 2 weeks). At 3 months, moderate improvement was observed; however, at 8 months, only sparse lichenified papules and some residual hyperpigmentation remained, and the patient reported a VAS score of 0.5 for pruritus compared to 9 at baseline.…”

Section: Resultsmentioning

confidence: 99%

“…Thus, there are similarities between PN and AD in terms of involvement of Th2 activation and the STAT pathway (Fukushi, Yamasaki, & Aiba, ). Hence, it has been hypothesized that blocking of IL‐4/13 with dupilumab could be beneficial in managing skin inflammation, which leads to pruritus (Calugareanu et al, ). Other hypotheses include involvement of the itch–scratch cycle mediated by an unusual neuroimmune interaction in the skin (Oetjen et al, ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dupilumab for prurigo nodularis: Case series and review of the literature

Holm

Agner

Sand

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin‐4 and interleukin‐13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off‐label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well‐tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1–4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well‐tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Dupilumab for prurigo nodularis: Case series and review of the literature

Holm

Agner

Sand

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…In recent months, 3 other reports of successful treatment of patients with CPG using dupilumab have been published (10)(11)(12). All case reports (totalling 11 patients with CPG) have in common that most patients have had chronic prurigo for many years and that numerous different therapies have previously been carried out without success (Table SI 1 ).…”

Section: Discussionmentioning

confidence: 99%

Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review

Almustafa¹,

Weller²,

Autenrieth³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

“…Studies suggest the implication of the Th2 cytokine pathway [interleukin 4 (IL-4) and interleukin 13 (IL-13)] in its pathogenesis, 2 evidenced by recent monocentric case series showing the efficacy of IL-4 and IL-13 blocker (dupilumab) for PN treatment. [3][4][5][6][7][8] This study aimed to retrospectively determine the efficacy and safety of dupilumab treatment within a French multicentric cohort of 16 adult patients with chronic PN refractory to multimodal treatment regimens (April 2017-August 2019). Patients were classified as atopic (n = 7) and non-atopic PN (n = 9) as previously described.…”

mentioning

confidence: 99%

Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients

Călugăreanu

Jachiet

Tauber

et al. 2019

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

The notion that it is related to M. lepromatosis may be true according to some authors. However, others showed that the correlation is not that strong, looking at leprosy clinical types in different countries 6 ; M. lepromatosis may resemble M. leprae in causing different manifestations depending on the host immunity. 2 From the group around Rea and Modlin, Maria Achoa reported at the World Congress Dermatology in Milano that of their Mexican patients with lepra bonita, the majority was indeed infected with M. lepromatosis, while some had a single M. leprae infection or a mixed infection. Whether M. lepromatosis affects the internal organs more than M. leprae is yet to be proven. The difference in the type of infection may in part account for clinical and geographical variabilities associated with leprosy infection; however, according to our opinion, the survival of the bacilli in the environment and the socioeconomic factors are relatively more important. For the practising dermatologist, the bacilli causing leprosy are of academic interest only. The treatment is the same, and it is the resistance to therapy that counts. As far as the role of physical medicine is concerned, she is right, but to direct this requires publishing of another article.

show abstract

Dramatic improvement of generalized prurigo nodularis with dupilumab

Cited by 31 publications

References 4 publications

Dupilumab for prurigo nodularis: Case series and review of the literature

Dupilumab for prurigo nodularis: Case series and review of the literature

Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review

Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients

Contact Info

Product

Resources

About